MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge a number of intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Main demo goals ended up To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although among the https://georgesg544tev0.blog-ezine.com/profile